Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 22.12.2025 1 Am J Epidemiol 1 Ann Oncol 6 Ann Surg Oncol 4 BMC Cancer 1 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Auckl) 4 Breast Cancer (Dove Med Press) 4 Breast Cancer Res 1 Breast Cancer Res Treat 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Res 1 Clin Breast Cancer 2 Clin Cancer Res 2 Eur J Cancer 6 Eur Radiol 2 Histopathology 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 2 J Clin Invest 4 J Natl Cancer Inst 1 J Surg Oncol 1 Mod Pathol 1 Nature 6 NPJ Breast Cancer 2 Oncogene 2 Oncol Rep 1 PLoS Comput Biol 5 PLoS One 1 Radiol Artif Intell 5 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Epidemiol

1. LIMA SM, Palermo TM, Tian L, Lee FF, et al
   Historical redlining, breast cancer survival, and the mediating and modifying role of contemporary neighborhood socioeconomic conditions.
   Am J Epidemiol. 2025 Dec 19:kwaf282. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. JHAVERI KL, Neven P, Casalnuovo ML, Kim SB, et al
   Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial.
   Ann Oncol. 2025 Dec 12:S0923-7534(25)06289-1. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. BEERTHUIZEN AWJ, Snellen TIM, Bartels SA, Kuijer A, et al
   The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial.
   Ann Surg Oncol. 2025 Dec 14. doi: 10.1245/s10434-025-18833.
   PubMed         Abstract available
   
   
4. MA D, Cao H, Wu J, Shang T, et al
   ASO Visual Abstract: Analysis of the Current Status of de Novo Metastatic Breast Cancer Surgery in China and the United States: A Multicenter Real-World Study.
   Ann Surg Oncol. 2025 Dec 16. doi: 10.1245/s10434-025-18868.
   PubMed        
   
   
5. RAYMAKERS AM, King TA, Mittendorf EA, Dey T, et al
   Impact of Breast Cancer-Related Lymphedema on Cancer Care Costs: Longitudinal and Age-Based Analyses.
   Ann Surg Oncol. 2025 Dec 16. doi: 10.1245/s10434-025-18875.
   PubMed         Abstract available
   
   
6. ROSS VMS, Addie M, Roy Pickard M, Josey V, et al
   ASO Author Reflections: Neoadjuvant Chemotherapy and Prediction of Residual Axillary Disease in Breast Cancer Patients.
   Ann Surg Oncol. 2025 Dec 16. doi: 10.1245/s10434-025-18905.
   PubMed        
   
   
7. LEE JA, Lee HS, Jeon S, Kim D, et al
   ASO Visual Abstract: Risk Factors and Incidence of Reoperation in Direct-to-Implant Breast Reconstruction Surgery Among Patients with Breast Cancer.
   Ann Surg Oncol. 2025 Dec 17. doi: 10.1245/s10434-025-18845.
   PubMed        
   
   
8. VAN GEMERT D, Beelen LM, Mos J, van Egdom L, et al
   ASO Visual Abstract: Breast Cancer-Related Lymphedema (BCRL): Comprehensive Characterization of Patients Seeking Microsurgical Treatment.
   Ann Surg Oncol. 2025 Dec 17. doi: 10.1245/s10434-025-18861.
   PubMed        
   
   

   
   BMC Cancer

9. XIE H, Zhang J, Li Q, Tan T, et al
   Enhancing breast cancer diagnosis: non-invasive prediction of MKI-67 (Ki67) expression using ultrasound images.
   BMC Cancer. 2025 Dec 15. doi: 10.1186/s12885-025-15443.
   PubMed         Abstract available
   
   
10. YILMAZ S, Yur M
    CA 15 - 3 may be a promising biomarker for differentiating distant organ metastasis in breast cancer at initial diagnosis.
    BMC Cancer. 2025 Dec 15. doi: 10.1186/s12885-025-15463.
    PubMed         Abstract available
    
    
11. HEIDINGER M, Staehelin S, Halbeisen FS, Maggi N, et al
    Impact of bilateral surgery on time to treatment in patients with breast cancer undergoing mastectomy - a retrospective cohort study.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15389.
    PubMed         Abstract available
    
    
12. ALHALABI A, Abdo T, Hijazi A, Mohanna M, et al
    Factors associated with developing and surviving brain metastases in patients with breast cancer: a multi-center experience.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15422.
    PubMed         Abstract available
    
    

    
    Br J Cancer

13. GUPTA K, Koelsch N, Neely V, Graham L, et al
    Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.
    Br J Cancer. 2025 Dec 15. doi: 10.1038/s41416-025-03292.
    PubMed         Abstract available
    
    

    
    Breast Cancer

14. YAMAGUCHI K, Egashira R, Nakazono T, Yoshinaga Y, et al
    CT findings of lung injury during breast cancer treatment.
    Breast Cancer. 2025 Dec 19. doi: 10.1007/s12282-025-01816.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

15. AKITA Y, Iwase M, Kikumori T, Takeuchi D, et al
    Clinical and Pathological Characteristics and Treatment Implications of BRCA1- and BRCA2-Mutated Breast Cancer in Japanese Patients: A Single-Institution Retrospective Study.
    Breast Cancer (Auckl). 2025;19:11782234251399355.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

16. BUYUKASIK S, Kankaya B, Altundal YE, Ozgul M, et al
    Beyond The Age Limit: A Comparative Study (<70 Vs >/=70 Years) in Breast Cancer Characteristics and Surgical Management in Women.
    Breast Cancer (Dove Med Press). 2025;17:1231-1246.
    PubMed         Abstract available
    
    
17. HUANG Y, Meng Y, Lou X, Feng D, et al
    The Modified Shuyu Pill Inhibits the Formation of Pre-Metastatic Niches in Triple-Negative Breast Cancer by Reducing the Number of Myeloid-Derived Suppressor Cells (MDSCs) via the JAK2/STAT3 Pathway.
    Breast Cancer (Dove Med Press). 2025;17:1213-1229.
    PubMed         Abstract available
    
    
18. REN D, Xue D, Hou Z, Xu H, et al
    ST6GAL1 Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer via the HIF-HK2 Signaling Pathway.
    Breast Cancer (Dove Med Press). 2025;17:1199-1211.
    PubMed         Abstract available
    
    
19. ZHANG D, Guan Y, Tang H, Xue Q, et al
    Common Biomarkers and Pathogenesis of Inflammatory Bowel Disease and Breast Cancer: Mendelian Randomization and Multi-Omics Studies.
    Breast Cancer (Dove Med Press). 2025;17:1183-1197.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

20. GUHA A, Sultana J, Bhuniya A, Chakravarti M, et al
    Tumor-educated-platelets interact with breast cancer-stem-cells via P-selectin-PSGL1 and ensure stemness and metastasis through WNT-beta-catenin-VEGF-VEGFR2 intra-cellular signaling: therapeutic modulation by aspirin.
    Breast Cancer Res. 2025 Dec 15. doi: 10.1186/s13058-025-02185.
    PubMed         Abstract available
    
    
21. HU S, Ji A, Wang M, Li X, et al
    MAP3K1/MAP2K4 mutations drive breast cancer progression by compensating for TP53 loss through inactivation of the JNK2-p53-FOSL1 axis.
    Breast Cancer Res. 2025 Dec 16. doi: 10.1186/s13058-025-02195.
    PubMed         Abstract available
    
    
22. BARDWELL SPELTZ L, Ghosh K, Visscher DW, Scott CG, et al
    Histologic correlates of background parenchymal uptake on molecular breast imaging.
    Breast Cancer Res. 2025;27:216.
    PubMed         Abstract available
    
    
23. WANG D, Luo S, Yu R, Wen D, et al
    ALDH3A2 targets arachidonic acid to promote cell metastasis in TNBC via AMPK/m-TOR signaling pathway.
    Breast Cancer Res. 2025;27:217.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

24. SCHUPP E, Gokun Y, Eckstein J, Stover DG, et al
    Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer.
    Breast Cancer Res Treat. 2025;215:43.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

25. LUI ML, Lee Argov EJ, Kehm RD, Karr AG, et al
    Social Drivers of Guideline- Discordant Breast Cancer Screening by Age and Mortality Risk.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Res

26. RYSER MD, Greenwald MA, Monyak D, Sorribes IC, et al
    Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics.
    Cancer Res. 2025;85:5084-5097.
    PubMed         Abstract available
    
    
27. XIA Z, Liu W, Guo D, Chen L, et al
    circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain.
    Cancer Res. 2025;85:4977-4994.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

28. HARRIS A, Conrardy R, Szabo A, Chaudhary LN, et al
    The Influence of Socioeconomic Status on Stage at Diagnosis and Survival in Young Breast Cancer Patients.
    Clin Breast Cancer. 2025;26:87-99.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

29. RUGO HS, Cescon DW, Robson ME, Im SA, et al
    KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
    Clin Cancer Res. 2025 Dec 17. doi: 10.1158/1078-0432.CCR-25-1818.
    PubMed         Abstract available
    
    
30. SANDOVAL JL, Kiavue N, Djerroudi L, Jacot W, et al
    Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.
    Clin Cancer Res. 2025;31:5178-5187.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

31. PENAULT-LLORCA F, Lusque A, Filleron T, Tran K, et al
    Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score(R) in node-positive breast cancer: Independent validation in the PACS-01 trial.
    Eur J Cancer. 2025;233:116152.
    PubMed         Abstract available
    
    
32. BOUTEILLER F, Gourgou S, Bringuier M, Galvin A, et al
    Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.
    Eur J Cancer. 2025;233:116166.
    PubMed         Abstract available
    
    

    
    Eur Radiol

33. AYDEMIR DG, Molwitz I, Beitzen-Heineke A, Chen H, et al
    Right ventricular and biatrial CMR strain analysis detects myocardial functional impairment after breast cancer therapy.
    Eur Radiol. 2025 Dec 19. doi: 10.1007/s00330-025-12257.
    PubMed         Abstract available
    
    
34. SACCENTI L, El Bejjani L, Dao TH
    Postmastectomy radiotherapy for early-stage breast cancer: can imaging bring us closer to personalized care?
    Eur Radiol. 2025 Dec 17. doi: 10.1007/s00330-025-12201.
    PubMed        
    
    
35. LYTH J, Gialias P, Husberg M, Bernfort L, et al
    Results from a Swedish model-based analysis of the cost-effectiveness of AI-assisted digital mammography.
    Eur Radiol. 2026;36:754-764.
    PubMed         Abstract available
    
    
36. ANDERMAN KJ, Daly AE, Newman AM, Dang PA, et al
    Placement of radiofrequency identification tags: Is there an optimal tag-to-target distance?
    Eur Radiol. 2026;36:64-72.
    PubMed         Abstract available
    
    
37. LIU G, Yang N, Qu Y, Chen G, et al
    Developing ultrasound-based machine learning models for accurate differentiation between sclerosing adenosis and invasive ductal carcinoma.
    Eur Radiol. 2026;36:33-44.
    PubMed         Abstract available
    
    
38. SEXAUER R, Riehle F, Borkowski K, Ruppert C, et al
    Enhancing breast positioning quality through real-time AI feedback.
    Eur Radiol. 2026;36:55-63.
    PubMed         Abstract available
    
    

    
    Histopathology

39. YE Q, Estrella J, Kalhor N, Liu A, et al
    TRPS1 expression in neuroendocrine neoplasms of breast and other organs.
    Histopathology. 2026;88:524-532.
    PubMed         Abstract available
    
    
40. HUANG CY, Wang YJ, Hsieh MS, Lin PY, et al
    Tumour-infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies.
    Histopathology. 2026;88:471-487.
    PubMed         Abstract available
    
    

    
    Int J Cancer

41. SCHMITZ RSJM, van den Belt-Dusebout AW, van Seijen M, Verschuur EAJ, et al
    Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic status.
    Int J Cancer. 2026;158:873-883.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

42. BOURGIER C, Mollevi C, Cowen D, Castan F, et al
    Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2026;124:109-121.
    PubMed         Abstract available
    
    

    
    J Biol Chem

43. LARIZ FJ, Hernandez S, Bautista-Tovar DC, Houston KD, et al
    IGFBP-6 Regulates Breast Cancer Cell Cycle Progression by Promoting Exit Out of G1.
    J Biol Chem. 2025 Dec 17:111069. doi: 10.1016/j.jbc.2025.111069.
    PubMed         Abstract available
    
    

    
    J Clin Invest

44. MA S, Han Y, Gu R, Chen Q, et al
    Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models.
    J Clin Invest. 2025;135:e180106.
    PubMed         Abstract available
    
    
45. ADACHI Y, Chen W, Zhang C, Wang T, et al
    Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy.
    J Clin Invest. 2025;135:e182394.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

46. KOTSOPOULOS J, Seca M, Gronwald J, Huzarski T, et al
    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
    J Natl Cancer Inst. 2025 Dec 17:djaf363. doi: 10.1093.
    PubMed         Abstract available
    
    
47. SEMPRINI J
    RE: Ambient air pollution and mortality in older patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 17:djaf369. doi: 10.1093.
    PubMed        
    
    
48. MATTICK LJ, Li CS, Lin PJ, Peppone LJ, et al
    Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 13:djaf360. doi: 10.1093.
    PubMed         Abstract available
    
    
49. NASSAR AH, Bou Farhat E, Abushukair H, Alchoueriy M, et al
    Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
    J Natl Cancer Inst. 2025 Dec 4:djaf344. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

50. ESGUEVA AJ, Tomatis M, Ponti A, Marotti L, et al
    Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database.
    J Surg Oncol. 2025 Dec 18. doi: 10.1002/jso.70158.
    PubMed         Abstract available
    
    

    
    Mod Pathol

51. HUANG X, Varambally S, Anderson SA, Bartow BB, et al
    A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18(INK4C) Expression in Advanced Breast Carcinoma.
    Mod Pathol. 2025;38:100841.
    PubMed         Abstract available
    
    

    
    Nature

52. HURSTING SD
    How fasting boosts breast cancer therapy.
    Nature. 2025 Dec 15. doi: 10.1038/d41586-025-03809.
    PubMed        
    
    

    
    NPJ Breast Cancer

53. LI Z, Kang D, Wang C, Ma J, et al
    Prognostic value of nuclear features based on tumor-associated collagen signatures in breast cancer.
    NPJ Breast Cancer. 2025 Dec 14. doi: 10.1038/s41523-025-00860.
    PubMed         Abstract available
    
    
54. ROTBAUER M, Dawe M, Nixon KCJ, Tsao J, et al
    The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancer.
    NPJ Breast Cancer. 2025 Dec 15. doi: 10.1038/s41523-025-00874.
    PubMed         Abstract available
    
    
55. O'REILLY S, Luis IV, Adam V, Razis ED, et al
    Author Correction: Advancing equitable access to innovation in breast cancer.
    NPJ Breast Cancer. 2025;11:140.
    PubMed        
    
    
56. FRASCARELLI C, Venetis K, Marra A, Concardi A, et al
    Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models.
    NPJ Breast Cancer. 2025;11:141.
    PubMed         Abstract available
    
    
57. WANG J, Dong Y, Lun W, Nai M, et al
    PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination.
    NPJ Breast Cancer. 2025;11:143.
    PubMed         Abstract available
    
    
58. ROUSSEL-SIMONIN C, Fernandez-Martinez A, Postel-Vinay S, Mosele F, et al
    Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine.
    NPJ Breast Cancer. 2025 Dec 19. doi: 10.1038/s41523-025-00858.
    PubMed         Abstract available
    
    

    
    Oncogene

59. WISNIEWSKI DJ, Voeller D, Addissie YA, Deshmukh SK, et al
    EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.
    Oncogene. 2026;45:15-25.
    PubMed         Abstract available
    
    
60. DEY P, Bishnu A, Patel J, Mishra S, et al
    Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
    Oncogene. 2025 Dec 15. doi: 10.1038/s41388-025-03653.
    PubMed        
    
    

    
    Oncol Rep

61. ICHIHARA T, Hayashi Y, Sato T, Iguchi M, et al
    Hypoxia?mediated Krebs von den Lungen?6 expression in breast cancer: Implications for tumor invasion and metastasis.
    Oncol Rep. 2026;55:35.
    PubMed         Abstract available
    
    
62. ZHANG X, Zhang Y, Li Y
    [Retracted] beta?elemene decreases cell invasion by upregulating E?cadherin expression in MCF?7 human breast cancer cells.
    Oncol Rep. 2026;55:34.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

63. HAN C, Song Z, Xu Z, Chen J, et al
    MAGNET: Multi-view graph autoencoder with cell-gene attention for cell interaction network reconstruction from spatial transcriptomics.
    PLoS Comput Biol. 2025;21:e1013810.
    PubMed         Abstract available
    
    

    
    PLoS One

64. ALMUTAIRI MH, Alrubie TM
    Contrasting effects of DNA demethylation on cancer-germline gene expression in breast cancer and leukemia cells.
    PLoS One. 2025;20:e0339460.
    PubMed         Abstract available
    
    
65. 
    Retraction: Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis.
    PLoS One. 2025;20:e0339149.
    PubMed        
    
    
66. 
    Expression of Concern: Utilization of complementary and alternative medicine (CAM) by women with breast cancer or gynecological cancer.
    PLoS One. 2025;20:e0339083.
    PubMed        
    
    
67. BINTABARA D, Kamata CC, Mohamedi R, Basinda N, et al
    Spatial autocorrelation and determinants of low uptake of breast cancer screening among women of reproductive age: A mixed-effect multilevel analysis of Tanzanian population-based survey.
    PLoS One. 2025;20:e0338337.
    PubMed         Abstract available
    
    
68. EL-TANANI M, Satyam SM, Rabbani SA, El-Tanani Y, et al
    Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines.
    PLoS One. 2025;20:e0338027.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

69. CHANG YW, Ryu JK, An JK, Choi N, et al
    Breast Cancers Detected and Missed by AI-CAD: Results from the AI-STREAM Trial.
    Radiol Artif Intell. 2026;8:e250281.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

70. MINK VAN DER MOLEN DR, Batenburg MCT, van 't Westeinde T, Houweling AC, et al
    Acute toxicity and quality of life after 5-fraction versus 15-fraction adjuvant radiotherapy following conventional or oncoplastic breast-conserving surgery - a real-world prospective cohort study.
    Radiother Oncol. 2026;214:111310.
    PubMed         Abstract available
    
    
71. SALVESTRINI V, Marrazzo L, Barletta G, Becherini C, et al
    Cardiac safety of ultra-hypofractionated whole breast irradiation: Results from the SAFE-FORWARD observational prospective cohort study.
    Radiother Oncol. 2026;214:111267.
    PubMed         Abstract available
    
    
72. HOVENIER R, Huele EH, Bindels BJJ, van Oss A, et al
    Pain response of patients treated with radiotherapy for painful bone metastases between 2013 and 2024 - An analysis of the prospective real-world PRESENT cohort.
    Radiother Oncol. 2026;214:111263.
    PubMed         Abstract available
    
    
73. BRION T, Balde M, Allodji R, Rossier C, et al
    Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial.
    Radiother Oncol. 2026;214:111202.
    PubMed         Abstract available
    
    
74. LICHTER KE, Asaro A, Qureshi MM, Truong MT, et al
    The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
    Radiother Oncol. 2026;214:111161.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.